Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol

   Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical
                            Results For Naloxegol

Call Scheduled for Monday, November 12, 2012 at 8:15 AM EST/5:15 AM PST

PR Newswire

SAN FRANCISCO, Nov. 12, 2012

SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:
NKTR) will host a conference call with investors to discuss the positive Phase
3 clinical results announced by its partner AstraZeneca. Howard Robin,
president and chief executive officer, will host the conference call, which
will begin at 8:15 a.m. Eastern Standard Time (EST)/5:15 a.m. Pacific Standard
Time (PST).

A live audio-only Webcast of this conference call can be accessed through a
link that is posted on the home page of the Nektar website: The web broadcast of the conference call will be
available for replay through Thursday, December 13, 2012.

To access the conference call live by telephone, please follow these

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 70465377 (Nektar Therapeutics is the host)

Atelephonic replay will also be available shortly following the call and can
be accessed by dialing (855) 859-2056 (U.S.); or (404) 537-3406
(international) with a passcode of 70465377. The replay will be available for
approximately four weeks following the call.

In the event that any non-GAAP financial measure is discussed on the
conference call that is not described in the press release, or explained on
the conference call, related information will be made available on the
Investor Relations page at the Nektar website as soon as practical after the
conclusion of the conference call.

This call will replace the company's regular financial results call which was
scheduled for Tuesday, November 13, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet
for the treatment of opioid-induced constipation. This agreement also
includes NKTR-119, an earlier stage development program that is a
co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid
analgesic candidate for chronic pain conditions, is in Phase 2 development in
osteoarthritis patients with chronic knee pain.NKTR-192, a novel mu-opioid
analgesic in development to treat acute pain is in Phase 1 clinical
development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in
a Phase 3 clinical study (the BEACON study) for the treatment of metastatic
breast cancer and is also in Phase 2 studies for the treatment of ovarian and
colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including
Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta®
for neutropenia.Additional development-stage products that leverage Nektar's
proprietary technology platform include Baxter's BAX 855, a long-acting
PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India.Further information
about the company and its drug development programs and capabilities may be
found online at

CONTACT: Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585

SOURCE Nektar Therapeutics

Press spacebar to pause and continue. Press esc to stop.